A cancer patient's perspective: Marty's story and spectral CT

Marty didn’t need another test. He needed clarity. Spectral CT is designed to reveal what conventional CT cannot: a deeper, more precise differentiation of tissues, clearer visualization of iodine and the ability to unmask lesions that otherwise appear ambiguous. It replaces uncertainty with insight—when insight is needed most.

Had he received spectral CT early in his journey, his care team could have seen the tumor clearly from the start—months earlier. The information was there, hiding in plain sight. Spectral CT simply makes it visible.

This is why Philips leads in spectral CT. Not innovation for innovation’s sake, but proven technology that delivers confidence when clinicians need it most.

Instead of Marty undergoing 16 imaging exams, he could have needed just 2–3, significantly reducing his exposure to radiation—from 160–180 mSv (the equivalent of about 8,000 X-rays) down to 30–40 mSv—and cutting contrast injections from seven to just two. This more efficient approach could have lowered his out-of-pocket costs from $20,000 to around $5,000. Most importantly, rather than waiting seven months for treatment, he could have been diagnosed in under two weeks and started treatment within just six weeks of his initial appointment.